Trickle is eyeing CRL again. If it hits its numbers -- and it appears to be on track -- this is very cheap: PE of about 16, earnings growth of about 20%, yielding a PEG ratio of .75. Likely Trickle's next purchase.
>>WILMINGTON, Mass.--(BUSINESS WIRE)--March 17, 2003--Charles River Laboratories' (NYSE:CRL - News) Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F. Ackerman will present on Tuesday, March 18, at the S.G Cowen 23rd Annual Health Care Conference in Boston. In conjunction with that presentation, and in keeping with the requirements of SEC Regulation FD, Charles River confirmed today that for the first quarter of 2003, earnings are expected to be in the range of $0.39 to $0.41 per fully-diluted share based on expected net sales growth of approximately 13% to 14%. <<
snip
Cheers, Tuck |
